ArticlePloS one2025
Integrated bioinformatics and experimental validation identify ATF3 as a key gene in secondary brain damage after intracerebral hemorrhage.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSecondary brain injury following intracerebral hemorrhage (ICH) is a critical clinical challenge, yet the molecular mechanisms driving neuronal damage remain poorly understood. This study investigates the role of the transcription factor ATF3 and its downstream effector, VASP, in mediating neuronal injury via the platelet activation pathways.
methodsDifferential gene expression analysis of the GSE24265 dataset was conducted using the limma package in R to identify key regulators in hemorrhagic conditions. Protein-protein interaction network analysis and bioinformatic predictions were employed to pinpoint central regulatory nodes and downstream targets. Validation experiments utilized the HT22 mouse hippocampal neuronal cell line, combining ATF3 overexpression/knockdown, dual luciferase reporter assays, and functional assessments (propidium iodide/Calcein-AM staining, flow cytometry). Enrichment analysis linked identified targets to biological pathways.
resultsATF3 was significantly upregulated in hemorrhagic conditions and identified as a central regulatory node. Bioinformatic and experimental validation confirmed VASP as a direct downstream target of ATF3. Enrichment analysis revealed VASP's predominant association with platelet activation pathways. Functional assays demonstrated that ATF3 overexpression exacerbated heme-induced cytotoxicity in HT22 cells, implicating hyperactive platelet activation in secondary neuronal damage.
conclusionsThis study identifies a novel ATF3-VASP signaling axis as a key driver of secondary neuronal injury post-ICH. Our findings advance the mechanistic understanding of post-hemorrhagic brain damage and suggest that therapeutic targeting of the ATF3-VASP pathway may mitigate secondary injury, offering a potential strategy to improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.